BLAINTRAVENOUSSOLUTIONPriority Review
Approved
Sep 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
KEYTRUDA (pembrolizumab) by Merck & Co. is programmed death receptor-1-directed antibody interactions [moa]. Approved for programmed death receptor-1 blocking antibody [epc]. First approved in 2014.
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KEYTRUDA (pembrolizumab) is a monoclonal antibody that blocks the Programmed Death Receptor-1 (PD-1), a checkpoint inhibitor that enhances anti-tumor immune response. Approved by the FDA on September 4, 2014, it is administered intravenously as a solution and represents a foundational immunotherapy across multiple cancer indications. The drug works by releasing the brakes on T-cell mediated immunity, allowing the immune system to recognize and attack cancer cells more effectively. KEYTRUDA is positioned as a standard-of-care first-line and combination therapy across melanoma, non-small cell lung cancer, head and neck cancers, and other solid tumors.
$0.1BPart D
Mechanism of Action
Programmed Death Receptor-1-directed Antibody Interactions
Pharmacologic Class:
Programmed Death Receptor-1 Blocking Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product, MO-03, in Patients With Early Stage Triple Negative Breast Cancer
Started Sep 2026
50 enrolled
TNBC - Triple-Negative Breast CancerTNBCEarly Stage Triple-Negative Breast Carcinoma
Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and Keytruda® as Adjuvant Monotherapy in Patients With Melanoma
Started Aug 2026
138 enrolled
Adult Patients With Stage IIB, IIC, and Stage III Melanoma Following Complete Resection (Adjuvant Settings)
A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)
Started Jun 2026
20 enrolled
Malignant NeoplasmCarcinoma, Merkel CellLymphoma
Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
Started Jun 2026
45 enrolled
Head and Neck Squamous Cell CarcinomaHPV-Negative Squamous Cell Carcinoma
Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma
Started Jun 2026
820 enrolled
Gastric CancerGastroesophageal-junction CancerAdvanced Cancer
Worked on KEYTRUDA at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.